

Case PAT033001-US-PCT
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF ART UNIT: 1617
AITKEN, DAVID ET AL. EXAMINER: ZAREK, PAUL E
INTERNATIONAL APPLICATION NO: PCT/EP2004/003518
FILED: APRIL 02, 2004
U.S. APPLICATION NO: 10/550381
35 USC §371 DATE: SEPTEMBER 21, 2005
FOR: COMBINATIONS COMPRISING ANTI-EPILEPTIC DRUGS FOR
THE TREATMENT OF NEUROLOGICAL DISORDERS

MS: Amendment
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed:

☒ supplemental to the Information Disclosure Statement filed February 17, 2009.


If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to
Deposit Account No. 19-0134 in the name of Novartis.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the
references cited on the attached form(s) PTO-1449.

☒ Copies of the references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application
and indicate that each reference was considered by returning a copy of the initialed PTO 1449
form(s).

Respectfully submitted,



Daniel Woods
Attorney for Applicant
Reg. No. 59,864

Novartis Pharmaceuticals Corporation
One Health Plaza, Bldg. 101
East Hanover, NJ 07936
(862) 778-9587
Date: 10/19/09